Zenas BioPharma, Inc. (ZBIO)
NASDAQ: ZBIO · Real-Time Price · USD
17.29
-1.13 (-6.13%)
Sep 26, 2024, 4:00 PM EDT - Market closed
Zenas BioPharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 |
| Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| Revenue | 50 | 50 | - |
| Cost of Revenue | 86.22 | 60.03 | 61.69 |
| Gross Profit | -36.22 | -10.03 | -61.69 |
| Selling, General & Admin | 20.21 | 17.11 | 13.51 |
| Operating Expenses | 20.21 | 17.11 | 13.51 |
| Operating Income | -56.44 | -27.15 | -75.2 |
| Interest & Investment Income | 0.7 | 0.7 | - |
| Other Non Operating Income (Expenses) | 1.28 | -0.38 | -43.08 |
| EBT Excluding Unusual Items | -54.46 | -26.82 | -118.28 |
| Pretax Income | -54.46 | -36.82 | -119.28 |
| Income Tax Expense | 0.3 | 0.3 | - |
| Net Income | -54.76 | -37.12 | -119.28 |
| Net Income to Common | -54.76 | -37.12 | -119.28 |
| Shares Outstanding (Basic) | 13 | 13 | 13 |
| Shares Outstanding (Diluted) | 13 | 13 | 13 |
| Shares Change (YoY) | 3.89% | 2.62% | - |
| EPS (Basic) | -4.07 | -2.79 | -9.21 |
| EPS (Diluted) | -4.07 | -2.79 | -9.21 |
| Free Cash Flow | -33.69 | -30.55 | -65.85 |
| Free Cash Flow Per Share | -2.50 | -2.30 | -5.08 |
| Gross Margin | -72.45% | -20.07% | - |
| Operating Margin | -112.87% | -54.29% | - |
| Profit Margin | -109.51% | -74.25% | - |
| Free Cash Flow Margin | -67.38% | -61.09% | - |
| EBITDA | -56.31 | -27.03 | -75.12 |
| EBITDA Margin | -112.62% | -54.07% | - |
| D&A For EBITDA | 0.12 | 0.11 | 0.08 |
| EBIT | -56.44 | -27.15 | -75.2 |
| EBIT Margin | -112.87% | -54.29% | - |
| Revenue as Reported | 50 | 50 | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.